A Berdelou
Overview
Explore the profile of A Berdelou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lamartina L, Godbert Y, Nascimento C, Do Cao C, Hescot S, Borget I, et al.
Endocrine
. 2020 Mar;
69(1):133-141.
PMID: 32147774
Purpose: Differentiated thyroid cancer (DTC) patients with an unresectable primary tumor cannot benefit from curative surgery, and radioiodine treatment for locoregional and distant disease is not possible with the thyroid...
2.
Barat M, Tselikas L, de Baere T, Gravel G, Yevich S, Delpla A, et al.
Eur J Radiol
. 2019 Oct;
121:108693.
PMID: 31594669
No abstract available.
3.
Barat M, Tselikas L, de Baere T, Gravel G, Yevich S, Delpla A, et al.
Eur J Radiol
. 2019 Sep;
119:108650.
PMID: 31525680
Purpose: To evaluate a strategy that used thermal-ablation of vertebral metastases (VM) to prevent vertebral related events (VRE) in patients with differentiated thyroid cancer (DTC). Methods: This single center study...
4.
Hescot S, Haissaguerre M, Pautier P, Kuhn E, Schlumberger M, Berdelou A
Eur J Cancer
. 2018 May;
97:57-58.
PMID: 29731229
No abstract available.
5.
Walter T, Planchard D, Bouledrak K, Scoazec J, Souquet P, Dussol A, et al.
Lung Cancer
. 2016 May;
96:68-73.
PMID: 27133753
Objectives: The aim of this retrospective study was to analyse the efficacy of gemcitabine-oxaliplatin (gemox) or 5-fluorouracil-oxaliplatin (folfox) in the treatment of metastatic pulmonary carcinoid tumors. Patients And Methods: 45...
6.
Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, et al.
J Clin Endocrinol Metab
. 2016 Apr;
101(7):2733-41.
PMID: 27082933
Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) are the mainstay of advanced thyroid cancer (TC) treatment. Concern is rising about TKI-related toxicity. Objective: To determine the incidence and to investigate the...
7.
Michot J, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al.
Eur J Cancer
. 2016 Jan;
54:139-148.
PMID: 26765102
Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first...
8.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al.
Ann Oncol
. 2015 Dec;
27(4):559-74.
PMID: 26715621
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers. Therefore, their use...
9.
Hadoux J, Malka D, Planchard D, Scoazec J, Caramella C, Guigay J, et al.
Endocr Relat Cancer
. 2015 Mar;
22(3):289-98.
PMID: 25770151
There is no standard for second-line chemotherapy in poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC) patients. We analyzed the antitumor efficacy of 5-fluorouracil and oxaliplatin (FOLFOX) chemotherapy in this population....
10.
Lepoutre-Lussey C, Caramella C, Bidault F, Deandreis D, Berdelou A, Al Ghuzlan A, et al.
Eur J Nucl Med Mol Imaging
. 2015 Feb;
42(6):868-76.
PMID: 25676472
Purpose: Specific recommendations on screening modalities for paraganglioma (PGL) and phaeochromocytoma (PCC) in asymptomatic SDHx mutation carriers (relatives) are still lacking. We evaluated the added value of (18)F-FDG PET/CT in...